Cocaine vaccine enters human testing
NCT ID NCT02455479
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a vaccine called dAd5GNE in 150 people who are dependent on cocaine. The vaccine is designed to train the immune system to attack cocaine, preventing it from reaching the brain and causing a high. The main goal is to check if the vaccine is safe, while also measuring whether it reduces cocaine use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dAd5GNE vaccine
- What this could lead to
- If it works, this vaccine could help people with cocaine dependence by reducing cravings and preventing relapse.
- What could go wrong
- This is a very early phase 1 trial focused on safety, so it may not prove effective. The vaccine may not produce strong enough immunity to block cocaine's effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COCAINE DEPENDENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
WCMC Department of Genetic Medicine
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.